Project Grant R21AG085486
Award Date
9/1/24
Completion Date
6/30/26
Dollars Obligated
$449K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $328,000.00 to The Regents of the University of California, San Francisco to conduct the "Alzheimer's Disease Organelle Proteome Task (ADOPT) - Pilot Phase" project. The goal is to use genetic organelle tagging to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse model brains. The project will then perform mass spectrometry experiments to quantitatively...
This federal Project Grant award of $794,341.00, provided by the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) program, is funding research to investigate the mechanistic roles of cellular senescence and blood-brain barrier dysfunction in mediating pathogen-induced Alzheimer's disease (AD) progression. The key goals are to leverage experimental mouse models, molecular characterization of endogenous retrovirus RNA sensing, and human iPSC models to elucidate how...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,027,220 to the Oklahoma Medical Research Foundation (OMRF) to investigate the role of the Major Histocompatibility Complex I (MHC-I) in regulating microglial function during aging and Alzheimer's disease. The research aims to determine if MHC-I expression modulates microglial reactivity and phagocytic phenotypes, impacts prodromal Alzheimer's disease symptoms and disease progression, and...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This federal Project Grant award, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), aims to understand the mechanisms responsible for autophagy defects in neurons affected by Alzheimer's disease (AD). The $749,030 grant, awarded on December 15, 2024, will support experiments with a transgenic AD mouse model to evaluate the effects of various pharmacological interventions targeting calcium signaling and autophagy. The goal is to validate novel...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $784,596 to Northeastern University to conduct comprehensive and cell type-specific proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The research aims to expand understanding of protein dysfunctions in AD by profiling multiple brain regions across a large AD patient cohort and tauopathy mouse models, as well as conducting...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the molecular mechanisms underlying the neurodegenerative function of a subset of microglia (the brain's immune cells) in Alzheimer's disease (AD). The $442,357 award, effective December 15, 2024 through November 30, 2029, supports research by the Research Foundation of the City University of New York's Advanced Science Research Center to investigate how cellular stress signaling,...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) program, provides $842,175 to the J. David Gladstone Institutes in San Francisco, CA to explore the role of the NOX2 enzyme in Alzheimer's disease (AD) pathology. The research aims to assess the therapeutic potential of a NOX2 inhibitor, GSK2795039, in mitigating A-beta and tau-mediated brain dysfunction, network hyperactivity, and glucose hypometabolism in AD mouse models. The...